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mon clinical problem worldwide. Most autologous skin grafting 
techniques applied today are based on transplanting split-thick-
ness skin from a donor site to the area of the defect. A significant 
problem using split-thickness skin is often the fact that donor 
sites for harvesting split-thickness skin are limited, especially if 
large skin defects have to be covered. An additional drawback of 
this method is the structure of split-thickness skin. It contains all 
of the epidermis, but only remnants of the dermis. This lack of 
dermal tissue frequently leads to significant scarring and wound 
contraction due to the lack of dermal regeneration within the 
wound area, resulting in non-ideal outcomes regarding function-
ality and cosmetics [1–4]. Therefore, split-thickness skin is often 
used in combination with a dermal template, such as Integra arti-
ficial skin [1, 3, 5–9], Matriderm® (MedSkin Solutions Dr. Su-
welack, Billerbeck, Deutschland) [4, 10, 11], or other collagen-
elastin scaffolds [2].
The above mentioned problems could be significantly reduced 
if a bio-engineered autologous skin substitute would be available.
Development of denovoDerm and denovoSkin
The Tissue Biology Research Unit of the University Children’s 
Hospital Zurich has developed in 15 years of research, in close col-
laboration of scientists and clinicians, autologous tissue-engineered 
skin grafts based on a collagen type I hydrogel which can be ap-
plied in one surgical intervention. These skin grafts have success-
fully been tested in pre-clinical studies [12–14]. Since 2013, the de-
veloped skin grafts are produced in the facilities of the Wyss Trans-
lational Center Zurich, Switzerland, under good manufacturing 
practice (GMP) conditions for clinical trials. In June 2014, a phase 
I clinical trial [15] was started at the University Children’s Hospital 
Zurich with the following two products (fig. 1):
– denovoDerm, an autologous tissue-engineered dermal graft 
used in combination with autologous split-thickness skin intra-
operatively.
Keywords
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Summary
Background: The treatment of severe full-thickness skin 
defects represents a significant and common clinical 
problem worldwide. A bio-engineered autologous skin 
substitute would significantly reduce the problems ob-
served with today’s gold standard. Methods: Within 15 
years of research, the Tissue Biology Research Unit of 
the University Children’s Hospital Zurich has developed 
autologous tissue-engineered skin grafts based on colla-
gen type I hydrogels. Those products are considered as 
advanced therapy medicinal products (ATMPs) and are 
routinely produced for clinical trials in a clean room facil-
ity following the guidelines for good manufacturing 
practice (GMP). This article focuses on hurdles observed 
for the translation of ATMPs from research into the GMP 
environment and clinical application. Results and Con-
clusion: Personalized medicine in the field of rare dis-
eases has great potential. However, ATMPs are mainly 
developed and promoted by academia, hospitals, and 
small companies, which face many obstacles such as 
high financial burdens.
© 2016 S. Karger GmbH, Freiburg
About denovoDerm and denovoSkin
Background
The treatment of severe full-thickness skin defects resulting 
from burns, congenital giant nevi, disfiguring scars, soft tissue 
trauma, and tumor resection represents a significant and com-
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– denovoSkin, an autologous tissue-engineered dermo-epider-
mal skin graft. As it includes a keratinocyte layer on the upper 
side, it does not need any additional coverage by split-thickness 
skin.
Both products are transplanted in a one-step surgery directly 
onto the wound bed [15]. 
Advanced Therapy Medicinal Products (ATMPs)
Definition of ATMPs
ATMPs are defined as medicinal products for human use which 
are either based on gene therapy, somatic cell therapy, tissue engi-
neering, or a combination of those. The previously described prod-
ucts denovoDerm and denovoSkin belong to this category, as a tis-
sue-engineered product is defined as a product containing or con-
sisting of engineered cells or tissues (from human and/or animal 
origin, viable or non-viable) and having properties used for regen-
eration, repair or replacing human tissue. In this context, the label 
‘tissue engineering’ is fulfilled if cells or tissues were substantially 
manipulated to achieve the desired biological characteristics, phys-
iological functions, or structural properties relevant for the planned 
mode of action. 
The field of ATMPs underwent large growth and changes in the 
past years. In many areas of medicine, new techniques and meth-
ods offer novel therapeutic approaches with the help of such 
products. 
With the introduction of the ATMP regulation of the European 
Medicines Agency [16], the legal framework for ATMPs was stan-
dardized in Europe:
– Centralized procedures for ATMPs were introduced.
– The Committee for Advanced Therapies (CAT) was estab-
lished.
– Tissue engineering was clearly defined.
– Cell-based products were clearly regulated.
Regarding manufacturing and testing of ATMPs, the ATMP 
regulation EC 1394/2007 [16] defines the standard. The manufac-
turing of ATMPs should be performed under conditions following 
the guidelines for GMP. The principles of GMP are described in 
the Commission Directive 2003/94/EC [17].
For quite some time, the status and classification of ATMPs in 
Europe was unclear, and significant variations among the different 
member states were observed [18]. This unsatisfactory situation 
was substantially improved by the introduction of the ATMP regu-
lation, and by the establishment of the CAT by the EMA in January 
2009. This multidisciplinary committee is responsible for assessing 
the quality, safety, and efficacy of ATMPs. Nevertheless, situations 
occur where national competent authorities of EU member states 
differ in the ATMP classification of a specific product [19].
Development of ATMPs
It appears that presently research and development of ATMPs is 
almost exclusively performed by academia, hospitals, and small 
((Fig. 1. Bemaßung 149,6 mm Breite, ohne rahmen, farbig)) 
 
 
 
Fig. 1. Overview on 
the production pro-
cess of (A) denovo-
Derm and (B) deno-
voSkin. A A skin bi-
opsy is removed from 
the patient and dermis 
and epidermis are 
separated. Fibroblasts 
are isolated and incor-
porated in a collagen 
type I hydrogel. The 
dermal substitute de-
novoDerm is trans-
planted onto the 
wound bed and cov-
ered with split-thick-
ness skin. B For deno-
voSkin, a skin biopsy 
is removed from the 
patient and dermis 
and epidermis are 
separated. Fibroblasts 
and keratinocytes are 
isolated. Fibroblasts 
are incorporated in a 
collagen type I hydro-
gel. After a cultivation phase, keratinocytes are seeded on top of this hydrogel. The dermo-epidermal skin substitute denovoSkin is transplanted onto the wound 
bed and does not require additional covering due to the epidermal cell layer on top of the hydrogel.
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companies. 80% of ATMPs currently under development are from 
academia [20]. Large pharma companies cannot be considered to 
be relevantly involved in the ATMP field [21], probably because 
niche products such as ATMPs are not very appealing for those. 
Especially for small ATMP developers the overview, deep under-
standing, and implementation of ATMP regulations and guidelines 
can be challenging. It has been argued that the ATMP standards, 
which were developed in collaboration with the pharmaceutical in-
dustry, would not always be compatible with the typical niche ap-
plications of ATMPs, as most of them are of autologous nature and 
produced per patient (or in very small batch sizes), making the up-
scaling extremely demanding [18]. Additionally, the workload gen-
erated by the standards of GMP and good clinical practice (GCP) is 
often underestimated [18]. Interestingly, a survey at European re-
search centers working with ATMPs showed that most of the par-
ticipating centers supported strict and careful ATMP regulation. 
None of the centers in this survey supported potential lower GMP 
standards for ATMPs than standard medicines or lower standards 
for academic groups [22].
Examples of Commercially Available ATMPs and ATMPs under 
Development
Several ATMP products for skin defects are commercially avail-
able. Some examples are described in the following. The product 
Apligraf® (Organogenesis Inc., Canton, MA, USA) for the treat-
ment of ulcers consists of keratinocytes and fibroblasts in a colla-
gen matrix. In contrast to denovoSkin, the cells are from allogeneic 
origin [23]. The product Dermagraft® (Organogenesis Inc.) con-
sists of allogeneic fibroblasts in a polyglactin matrix and is used for 
the treatment of diabetic foot ulcers [24]. Epicel® (Vericel, Cam-
bridge, MA, USA) consists of autologous keratinocytes and is used 
for the treatment of large burns [24]. Currently in a phase II trial is 
the product Tiscover® (A-SKIN, Amsterdam, The Netherlands) 
for the treatment of chronic wounds, consisting of autologous ke-
ratinocytes and fibroblasts. In contrast to denovoSkin, it is only 
available in small size [25]. Table 1 gives an overview on tissue-en-
gineered ATMPs for skin defects.
Hurdles to Produce ATMPs under GMP Conditions
Translation of a Research Process into a GMP Process
The translation of a successful research process into a process 
following the GMP guidelines is very challenging for a research 
group. Every small step of the perfectly established manufacturing 
process has to be analyzed for its suitability to the GMP production 
process. Adaptations have to be made at different levels, which are 
described in more detail in the following paragraphs.
Risk Management
Every team working on the translation of a research process 
into the GMP environment will have to deal with many risks 
throughout the process. Risks can affect any area of the process. It 
can include materials, i.e. that not all required material is available 
in GMP grade; risks for involved personnel, i.e. working with living 
tissue as starting material poses risks of transmitting pathogens to 
Table 1. Tissue-engineered ATMPs for skin defects
Product Manufacturer Active substance Indication Status
Allogeneic
Apligraf® [23] Organogenesis, USA allogeneic fibroblasts and  
keratinocytes in collagen matrix 
ulcers commercially available  
in the USA
Dermagraft® [61] Organogenesis, USA allogeneic fibroblasts on  
polyglactin
diabetic foot  
ulcer treatment
commercially available  
in the USA
FirstCover [62] Elanix Biotechnologies  
AG, Switzerland
fetal fibroblasts and  
keratinocytes in matrix
acute skin  
wound care
in development
Autologous
Engineered skin substitute
(Permaderm®) [64, 65]
Amarantus BioSciences,  
USA
autologous fibroblasts and 
keratinocytes in collagen matrix
severe burns in development
ODD for the treatment of  
severe burns granted by FDA
Tisscover® [25, 66] A-Skin, The Netherlands fibroblasts and epidermal sheet ulcers in development
Self-assembled skin 
substitute [67, 68]
CHU de Québec,  
Université Laval, Canada
fibroblasts and keratinocytes large burns in development
Epicel® [63] Vericel Corporation, USA autologous keratinocytes large burns commercially available in USA
denovoDerm [15] Tissue Biology Research  
Unit, University of  
Zurich, Switzerland
fibroblasts in collagen hydrogel skin defects in development
denovoSkin [15] Tissue Biology Research  
Unit, University of  
Zurich, Switzerland
fibroblasts in collagen hydrogel  
and keratinocytes
skin defects in development
ODD for the treatment of burns 
granted by EMA and Swissmedic
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staff or cross-contaminating other batches; or risks for the patients 
if for example the batch manufacturing has to be stopped due to 
contamination. Careful risk management ensures quality of the 
manufacturing process and ultimately safety of the patient [26]. 
General risk management includes the assessment, control, com-
munication and review of risks. Of advantage is a multidisciplinary 
team to perform risk management as they will bring different as-
pects into the discussions.
Risk management tools are valuable instruments to identify 
risks, their cause and effects, and possible measures to minimize it. 
A commonly used tool is the risk assessment based on the method 
of failure modes and effects analysis (FMEA). It is a systematic 
technique for assessing the risk of each component of a system, 
originally designed by the American army [27]. A complex process 
such as the manufacturing of an ATMP is divided into small man-
ageable production steps (e.g., starting materials, consumables, 
handling techniques, and equipment used). Possible failures for all 
steps with effects, causes, and possibilities of detecting the failures 
are listed. Scores are given according to severity, probability of oc-
currence, and probability of detection. Based on those scores, a risk 
priority number is calculated. According to a previously defined 
threshold for the risk priority number, actions to reduce the risk 
have to be taken. [27–29]
Documentation
Documentation is crucial to GMP [30]. It assures the traceabil-
ity in case of batch-specific problems, reduces the risk of mistakes 
by defining the complete process, ensures reproducibility, and con-
firms responsibilities by signatures. A precise and detailed docu-
mentation system has to be established, describing the complete 
manufacturing process [31]. This not only includes the manufac-
turing steps of the ATMP itself but also preparation protocols for 
culture media, solutions, and matrixes. Additionally, all used mate-
rials (starting materials and consumables) need to be described in 
detail. The documentation system can be structured on different 
levels, for example into standard operating procedures (SOPs), 
working instructions (WIs), and protocols. 
SOPs describe the frame and context of a standard process and 
general requirements. They are detailed, in line with actual prac-
tice, easy to understand, chronological, explicit, versioned, revised, 
and released. WIs describe one specific step in very detail. Proto-
cols are generated to document the performed work.
The complete manufacturing process for an ATMP will be de-
scribed in an investigational medicinal product dossier (IMPD) [32].
Starting Materials
Almost all starting materials used in research are declared by 
the manufacturer as ‘research use only’. As certain product certifi-
cates may not be available, the use of those materials under GMP 
conditions may only be approved by the authorities under special 
circumstances, meaning if no other option is available and on a 
risk-based assessment (for example according to FMEA). In the 
past years, GMP-grade materials have become more and more 
available. Additionally, many companies offer the production of 
GMP-grade materials based on customer request. However, those 
custom-made products are on a higher pricing level than the stan-
dard materials, which may be problematic for academia and ATMP 
production with low production volume. Modifying starting mate-
rials from research grade into GMP grade requires meticulous test-
ing of the new material for suitability.
Of special interest as starting material is the human tissue sam-
ple. It represents the core material for the ATMP production but at 
the same time it is the material with the highest variability and all 
but impossible to standardize. Before tissue removal, the following 
laboratory analysis have to be performed: HIV 1, HIV 2, HBV, 
HCV, and syphilis are minimally required, depending on the type 
of tissue and donor; additional tests can be mandatory [33]. It is 
advisable to provide detailed protocols on tissue sample removal. 
Nevertheless, the quality of incoming tissue might vary depending 
on the performing person, but mainly depending on the donor. 
Factors such as age, sex, donor area, metabolic activity, and inter-
donor variability will all influence the manufacturing process, but 
cannot be circumvented. The manufacturing process has to be sta-
ble enough to deal with this high variability of starting material, 
and manufacturing protocols should allow for minimal variations 
depending on the starting material. Additionally, In-process con-
trols (IPCs) should account for this variability, especially when de-
fining thresholds for acceptance criteria.
Careful evaluation of the material origin is required when using 
bovine material, as widely used in cell culture applications [32, 34, 
35].
Consumables
For manufacturing according to the GMP guidelines, single-use 
consumables are the first choice. Standard research consumables 
often are delivered in large quantities and multipacks. However, 
for GMP single-use single-packed sterile consumables are ideal and 
ease the routine production as no cleaning has to be performed and 
therefore the risk of cross-contamination can be minimized.
Re-usable material has to be checked carefully for its suitability 
for application under GMP conditions, with special regard to the 
risk of cross-contamination. Efficient cleaning has to be performed 
and validated, requiring material resistance to the chosen cleaning 
agent and cleaning method. Validated sterilization processes, in 
combination with the appropriate packaging, ensure the safety of 
the material.
IPCs
IPCs have to be established for the complete manufacturing 
process; they are used to address questions of two main categories: 
i) the safety of the product and ii) the quality of the product [36].
IPCs of the first category are used to ensure the safety of the 
product, certifying that for example a cell population used for the 
production of a tissue-engineered product is free of endotoxins 
and mycoplasma. Of course sterility is a parameter broadly and 
carefully checked. IPCs for the product quality are used to confirm 
that the manufactured product will correspond to the product au-
thorized by the regulatory authority. For example, cell populations 
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have to be analyzed on their identity and purity to ensure the ap-
propriate cells can be found in the final product in the defined 
number.
Controls based on the experience of the manufacturing staff are 
widely used in research; however, under GMP conditions such 
controls are difficult to perform in a standardized way and difficult 
to reproduce. Additionally, the outcome of a GMP manufacturing 
process should not depend on the manufacturing staff. Whenever 
possible, objective controls with measurable outcomes should be 
chosen. As an example, the microscopic assessment of the cell 
morphology of a population as identification tool should be re-
placed by immunofluorescence analysis, using specific markers for 
the cell type under investigation.
The establishment of such an IPC plan should be considered 
early in the translation of the research process into a GMP process, 
as the introduction of IPCs at different manufacturing steps might 
influence the further proceeding; for example, significantly higher 
initial cell numbers are required if flow cytometry quality analyses 
have to be performed.
Additional costs generated by IPCs may not be underestimated 
as such controls usually have to be performed in a GMP-accredited 
laboratory.
Release Controls
In addition to the IPCs conducted throughout the process on 
intermediate products and quality control samples, also the final 
product has to be analyzed for safety and quality by a so-called 
qualified person (QP). However, under routine production condi-
tions this is often not possible as analyzing methods are destructive 
or can be done only under non-sterile conditions. Therefore a plan 
has to be established specifying on which samples all required con-
trols can be executed. Validations have to be undertaken to ensure 
that the analyzed samples are representative for the final product.
Particular attention should be paid on the strategy regarding 
sterility of the final product. Widely used sterility methods, such as 
methods used for sterilization of medical devices or healthcare fa-
cilities (e.g., autoclave steam sterilization, ethylene oxide steriliza-
tion, or gamma ray sterilization [37, 38]), are not applicable for liv-
ing tissues. Hence, as no final sterilization can be performed, steril-
ity of the product has to be ensured during manufacturing, from 
starting materials to packaging materials for the final ATMP prod-
uct [39]. In addition to routine sterility tests during manufacturing, 
it is advisable that also the final product is analyzed for sterility, for 
example according the European Pharmacopoeia [40]. It should be 
taken into consideration that sterility analysis using the direct in-
oculation method will take approximately 14 days. When dealing 
with living ATMPs with their relatively short shelf life, clinical ap-
plication of the batch might therefore take place before final steril-
ity results are available, which will lead to a conditional release of 
the ATMP for transplantation. Other required release controls re-
garding product safety can include analysis for mycoplasma [41, 
42] and endotoxins [43, 44].
In addition to safety analysis of the final product, analysis re-
garding the functionality and performance should be included. De-
pending on the type of ATMP, this could comprise of the geomet-
rical structure of the product, the amount of living cells, the con-
centration of secreted factors, or any other component that is con-
sidered to be the active ingredient or mode of operation of the 
ATMP, as described in the IMPD.
Training of Staff
A crucial point for a successful GMP process is the staff [45]. 
The quality of the product is defined by the implementation of all 
documentation, protocols and controls by qualified staff with ex-
traordinary diligence. Training procedures involve training in 
standard GMP procedures, GMP facility-specific instructions such 
as hygiene measures, cleaning and monitoring, as well as extensive 
training on all documentation specific for the production process.
Approval by the Regulatory Authority
After successful establishment and validation of the entire GMP 
process, including methods, IPCs and release controls, the manu-
facturing process has to be approved by the regulatory authority.
The basis for approval by the regulatory authority is the investi-
gational medicinal product dossier (IMPD). It serves as core docu-
ment for the complete manufacturing process and describes infor-
mation regarding quality, manufacture, and control of the investi-
gational product. The structure of an IMPD is set out in the 
‘Guideline on the Requirements to the Chemical and Pharmaceuti-
cal Quality Documentation Concerning Investigational Medicinal 
Products in Clinical Trials’ [46] in connection to the Directive 
2001/20/EC [47].
Hurdles to Applying ATMPs in the Clinic
For notification of a clinical trial with an ATMP, an extensive 
dossier on the ATMP product has to be submitted to the regulatory 
authorities, including profound pre-clinical data [48–50].
As also shown by Pearce et al. [22], this leads to the use of far-
fetched animal models [51]. To perform pre-clinical testing on 
ATMPs, animal testing is standard, though the choice of the appro-
priate small and large animal model is challenging. ATMPs are 
based on human-specific (cell) sources and modes of action. How-
ever, a human-specific ATMP is either tested in an immune-incom-
petent system, or for immune-competent application the ATMP 
has to be transformed into an animal-specific (animal autologous) 
ATMP. When using immune-incompetent animals, such as nu/nu 
mice or rats [14, 52], it has to be taken into account that functional-
ity of the applied cells or bio-engineered tissues might differ from 
human application. Toxicity of human-specific biological material 
might be under- or overestimated due to species-specific side effects 
and pharmacologic activity. In addition, the enormous difference in 
life span may alter the results. When using immune-competent ani-
mals, as for example the pig as we did for the large-scale proof-of-
concept for denovoDerm and denovoSkin [53, 54], changes in raw 
materials such as cell culture media and growth factors for the pro-
duction of the animal-specific ATMP may introduce a source of in-
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accuracy to the test system. The study of Pearce et. al. [22] therefore 
suggests a paradigm shift in pre-clinical ATMP testing, suggesting 
first-in-man data to be used as part of the dossier for clinical trial 
authorization. Such first-in-man data, also referred to as phase 0 
study, then might be followed by a classic phase I trial.
A phase I trial is designed to assess the safety of the investiga-
tional product and to identify possible side effects [55]. For a clini-
cal phase I trial with a new product usually healthy, adult volun-
teers are recruited [56]. The main outcome for a phase I trial is 
safety, meaning it has to be shown that the investigational product 
can be applied without safety concerns.
Due to the nature of the tissue-engineered products denovo-
Derm and denovoSkin, this traditional set-up for the phase I trial 
was not appropriate. No healthy volunteers could be used, as the 
transplantation of the skin substitutes are only indicated on pre-
existing and severe skin defects, which are absent in healthy volun-
teers. For obvious reasons creation of such a skin defect would be 
unethical. Children would benefit the most of a tissue-engineered 
skin substitute as they still grow, and scar tissue has extremely ine-
lastic properties. Therefore, it was a straight-forward approach to 
go for the phase I trial directly into the population that would also 
gain most benefit of this innovative method.
This unconventional phase I design combined with the vulner-
able patient population asked for a close dialogue and collabora-
tion with the regulatory authorities and especially with the local 
ethical commission.
Establishing an independent data safety monitoring board 
(IDSMB) ensured an objective and unbiased point of view on the 
trial result, ensuring patient safety was warranted at any time of the 
trial. The IDSMB ideally is composed of experts from different 
fields such as ethics and the medical area of the investigational in-
dication to fully interpret and evaluate the safety of the study par-
ticipants. Each member of the IDSMB must be completely inde-
pendent and non-related to the trial. To avoid possible conflicts of 
interest, the members should not have any financial or other inter-
est that might influence objective data review and recommenda-
tions. The IDSMB serves to advise the sponsor and principal inves-
tigator of a trial with their expertise and recommendations.
The IDSMB has unrestricted access to all trial documents and 
source data at any time point. At critical steps of the trial, the 
IDSMB reviews the so far gained data and gives recommendations 
for the further procedure. 
Hurdles to Clinically Apply ATMPs in Europe
According to the ATMP regulation, an investigational medicinal 
product for application in clinical trials must be formally released 
for application by a QP. QPs are approved by the regulatory author-
ity and often have a pharmaceutical background. An issue identi-
fied by Pearce et al. [22] and also observed by us [57] is the hesita-
tion of QPs to take over responsibility for releasing an ATMP, as 
such products may not be part of their area of expertise. While we 
are in the comfortable situation that denovoDerm and denovoSkin 
products are manufactured in a certified GMP facility in Zurich 
[58] including release by a QP, difficulties were encountered when 
arranging import of the ATMPs to The Netherlands for an interna-
tional multicenter clinical trial. Although formally released in Swit-
zerland by an approved QP, for application of the products in The 
Netherlands the products need a second formal release after import 
by a local QP. Several QPs across The Netherlands refused the col-
laboration, and finding an appropriate solution was extremely time-
consuming. Additionally, hiring a QP for release of a single-batch-
sized patient-specific ATMP is extremely expensive and a logistic 
challenge due to the short shelf life of the products.
Transport of ATMPs across Europe is feasible, but poses high 
financial burdens on academic research groups. Due to the living 
nature of ATMPs, transport conditions require short transport 
times and controlled transport conditions, which often involve a 
tempered transport. Therefore, the collaboration with an appropri-
ate, ideally experienced logistic partner is essential for the success-
ful transport of ATMPs. 
Orphan Drug Designation (ODD): Dealing with  
Regulatory Agencies 
In several countries, including the EU, regulations for orphan 
drugs have been introduced, with the goal to stimulate research 
and development to foster the treatment of rare diseases. Signifi-
cant benefits can be achieved for products with an indication for 
the treatment of rare diseases. If certain criteria are fulfilled, ODD 
of a product can be granted, in the EU by the European Medicines 
Agency Committee for Orphan Medicinal Products (COMP). In 
the USA, this is the Office of Orphan Products Development 
(OOPD), a branch of the FDA, and in Switzerland the ODD is han-
dled by Swissmedic. The procedures for ODD in the USA and the 
EU are to a certain degree harmonized, but several differences still 
remain in the procedure [59]. For COMP ODD, the criteria to be 
met include [50, 60]:
– Intention for the treatment, prevention or diagnosis of a disease 
that is life-threatening or chronically debilitating
– Prevalence of condition in the EU and Switzerland ≤ 5 / 10,000 
patients, <200,000 patients/year in the US, or it is unlikely that 
marketing of a given medicine would generate sufficient re-
turns to justify investment for development
– No satisfactory method of diagnosis, prevention or treatment of 
condition or significant benefit to those affected by condition.
Benefits when receiving the ODD include incentives from the 
EU to develop a medicine for a rare disease such as reduced fees, 
fast track approaches to market authorization, and extended mar-
ket protection.
Commercialization of ATMPs
The production and commercialization of allogeneic skin 
ATMPs has been achieved in the recent past [23, 61] and will be 
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achieved in the near future [62]. These products are indeed living 
off-the-shelf products that can be manufactured using donor cells 
from biobanks, stored for relatively long time, and shipped without 
major hurdles. Epidermal autologous skin grafts [63], i.e. very sim-
ple and thin sheets produced starting off from patient’s material, 
have also entered the market, reaching, however, only a very small 
patient population, the severe burn patients with no real alternative 
therapeutic option. The poor clinical performance (severe scarring 
results after transplantation of epidermal sheets) and the high fra-
gility have negatively impacted the market penetration and thus 
the economic value, of these products. In contrast, the autologous 
dermo-epidermal skin grafts (table  1) have not yet reached the 
commercialization phase as they all are still in the process of ob-
taining their clinical validation. Nonetheless, these grafts have en-
tered the small-scale GMP production stage, and, clearly, the man-
ufacturing process is costly. All kinds of autologous ATMPs (be it 
bone, cartilage, cornea or skin) face the same challenge, but the 
autologous ATMPs represent the real breakthrough in regenerative 
medicine. A robust price analysis based on market potential, com-
petitive value, patient benefits / lack of existing technologies, and 
long-term healthcare savings must be run at a very early stage. In 
parallel, the reimbursement activities must be initiated to build up 
a constructive interface between manufacturer and health technol-
ogy assessment organizations on a national level (in EU at least) 
with the aim of defining and implementing an effective reimburse-
ment strategy. An example of success is represented by the first au-
tologous ATMP approved by EMA, Chondrocelect® (TiGenix 
(Leuven, Belgium), priced at ca. EUR 29,000.00 per injection), as 
for today, which is reimbursed in The Netherlands, UK, Germany, 
Spain, and Belgium. 
While, at least in Europe, there are a few possibilities to obtain 
funds to perform first-in-man trials (EU and nationals grants), lit-
tle grant money, if any, is available to finance the necessary but 
very expensive clinical trials as well as the regulatory, reimburse-
ment and marketing activities. A non-profit academia entity may 
represent an option, but such platforms are not easy to be estab-
lished since a substantial financial contribution would need to be 
acquired via charity and/or government agencies. Furthermore, 
these kinds of platforms may slow down the development process 
(due to scarce financial resources) and strongly limit the patient 
access to the technology. Thus, the creation of small and medium-
sized enterprises (SMEs) may represent an attractive solution to 
proceed with the product development in a faster and stable man-
ner. Clearly, the survival of such SMEs cannot be not solely linked 
to the treatment of the orphan burn indication. A robust business 
plan may further include the targeting of larger markets such as 
reconstructive and plastic surgery, chronic ulcers as well as 
cosmetics. 
Conclusion
The successful production of ATMPs for clinical application has 
to deal with many obstacles. Financial burdens often pose signifi-
cant risks to the ATMP project, especially when undertaken by ac-
ademia or SMEs. Finding the right partners is essential, as it is dif-
ficult for small manufacturers to establish some of the required as-
pects, such as GMP production. Despite the long list of hurdles, 
personalized medicine in the field of rare diseases has great poten-
tial and, if successful, may have a major impact on the welfare of 
affected patients.
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